胃腺癌患者 PROX1 表达与临床病理参数及预后的关系：荟萃分析和 TCGA 分析。

Lack of relationship between PROX1 expression and clinicopathological parameters and prognosis in gastric cancer patients: a meta-analysis and TCGA analysis.

机构信息

Department of Gastrointestinal Surgery, The Dalian Municipal Central Hospital Affiliated of Dalian Medical University, No. 826 Southwest Road Shahekou District, Dalian, 116033, People's Republic of China.

Department of Graduate School, Dalian Medical University, Dalian, People's Republic of China.

出版信息

BMC Gastroenterol. 2022 Mar 27;22(1):142. doi: 10.1186/s12876-022-02229-6.

DOI:10.1186/s12876-022-02229-6

PMID:35346069

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8958786/

Abstract

BACKGROUND

The relationship between PROX1 expression and clinicopathological characteristics and prognosis in patients with gastric cancer (GC) remain controversial. The aim of this study is to determine the clinicopathological and prognostic significance of PROX1 expression in patients with GC.

METHODS

A systematic literature search and meta-analysis were performed. Odds ratio (OR) and confidence interval (CI) were used to evaluated the relationship between PROX1 expression and clinicopathological characteristics and overall survival (OS) of GC patients. Additionally, the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) datasets were utilized to examine the relationship between PROX1 expression and clinicopathological significance and OS in GC patients.

RESULTS

A total of 8 studies pooling 1289 GC patients were included in the assessment. In GC patients, PROX1 expression was not related to gender (OR: 1.234, 95% CI 0.958-1.590, P = 0.104), depth of tumor invasion (OR: 0.742, 95% CI 0.428-1.287, P = 0.289), lymph node metastasis (OR: 2.161, 95% CI 0.808-5.779, P = 0.125), TNM stage (OR: 1.324, 95% CI 0.572-3.066, P = 0.513), tumor size (OR: 0.889, 95% CI 0.502-1.576, P = 0.687), distant metastasis (OR: 1.096, 95% CI 0.470-2.555, P = 0.763). In addition, we also found that PROX1 expression was not associated with 1-year OS (OR: 0.908, 95% CI 0.631-1.306, P = 0.602), 3-year OS (OR: 1.234, 95% CI 0.482-3.160, P = 0.661) and 5-year OS (OR: 0.853, 95% CI 0.266-2.736, P = 0.790). According to TCGA, in comparison with high and low PROX1 expression in GC patients, the OS did not differ statistically (p = 0.119).

CONCLUSION

The expression of PROX1 was shown to lack a significant relationship to gender, TNM stage, depth of invasion, tumor size, stage, distant metastasis, or lymph node metastasis in statistically. The expression of PROX1 was not related to OS and it failed to be a meaningful biomarker to prevent and diagnose GC.

摘要

背景

在胃癌（GC）患者中，PROX1 表达与临床病理特征和预后之间的关系仍存在争议。本研究旨在确定 PROX1 表达在 GC 患者中的临床病理和预后意义。

方法

进行了系统的文献检索和荟萃分析。比值比（OR）和置信区间（CI）用于评估 PROX1 表达与 GC 患者临床病理特征和总生存期（OS）之间的关系。此外，利用癌症基因组图谱（TCGA）和基因型组织表达（GTEx）数据集，研究了 PROX1 表达与 GC 患者临床病理意义和 OS 的关系。

结果

共纳入 8 项研究，共计 1289 例 GC 患者。在 GC 患者中，PROX1 表达与性别（OR：1.234，95%CI 0.958-1.590，P=0.104）、肿瘤浸润深度（OR：0.742，95%CI 0.428-1.287，P=0.289）、淋巴结转移（OR：2.161，95%CI 0.808-5.779，P=0.125）、TNM 分期（OR：1.324，95%CI 0.572-3.066，P=0.513）、肿瘤大小（OR：0.889，95%CI 0.502-1.576，P=0.687）、远处转移（OR：1.096，95%CI 0.470-2.555，P=0.763）无关。此外，我们还发现 PROX1 表达与 1 年 OS（OR：0.908，95%CI 0.631-1.306，P=0.602）、3 年 OS（OR：1.234，95%CI 0.482-3.160，P=0.661）和 5 年 OS（OR：0.853，95%CI 0.266-2.736，P=0.790）无关。根据 TCGA，与 GC 患者中 PROX1 高表达和低表达相比，OS 无统计学差异（p=0.119）。